Hematology-Oncology
Latest news
269 articles · 20 / page
Preclinical Progress of Glofitamab Combinations: Pioneering Therapeutics in Non-Hodgkin Lymphoma Management
Glofitamab, a CD20×CD3 T-cell engager, demonstrates promising synergistic effects in combination with chemotherapy and novel immunotherapies, addressing resistance mechanisms in non-Hodgkin lymphoma preclinical models and supporting future
Molecular Monitoring of MRD in Pediatric AML with KMT2A::MLLT10: Prognostic Insights and Clinical Impact
MRD monitoring by RT-qPCR in pediatric AML with KMT2A::MLLT10 fusion identifies patients at high risk despite morphologic remission, informing prognosis and guiding therapy.
Personalized Prediction of Platelet Transfusion Outcomes in Preterm Infants with Severe Thrombocytopenia
A dynamic model predicts individualized risk of major bleeding or death with or without prophylactic platelet transfusion in preterm infants, allowing tailored clinical decisions based on evolving patient status.
Ibrutinib-Rituximab versus Immunochemotherapy: A Paradigm Shift in First-Line Treatment for Older Mantle Cell Lymphoma Patients
The ENRICH trial demonstrates that ibrutinib combined with rituximab significantly improves progression-free survival compared to standard immunochemotherapy in older patients with untreated mantle cell lymphoma, heralding a new chemotherap
Evaluating Anemia-Related YouTube Videos: Reliable Education or Misinformation Risk?
A recent study assessed the quality, reliability, and popularity of anemia-related videos on YouTube, revealing moderate variability and highlighting the importance of health professionals’ involvement to ensure accurate online content.
Evaluating Radiation Risks from Medical Imaging in Pediatrics: Implications for Hematologic Cancer
A large cohort study links radiation exposure from pediatric medical imaging to a modest but significant increase in hematologic cancer risk, underlining the need for judicious imaging use in children and adolescents.
Advancing Chronic Lymphocytic Leukemia Management: The Impact of Measurable Residual Disease-Guided Ibrutinib-Venetoclax Therapy
Phase 3 trial data demonstrate that ibrutinib-venetoclax therapy achieves superior undetectable measurable residual disease rates and significantly prolonged progression-free survival compared with ibrutinib alone or FCR in chronic lymphocy
Oral Decitabine and Cedazuridine Maintenance Post-HSCT: Promising Strategy in High-Risk AML and MDS
A phase 2 trial demonstrates that oral hypomethylating agent ASTX727, with optional donor lymphocyte infusion, shows encouraging disease-free survival and manageable safety after stem-cell transplantation in very high-risk acute myeloid leu
Oral Decitabine and Cedazuridine as Maintenance Therapy Post-HSCT in Very High-Risk AML and MDS: Insights from the GFM-DACORAL-DLI Phase 2 Trial
A phase 2 trial demonstrates that oral decitabine and cedazuridine maintenance following hematopoietic stem-cell transplantation may improve disease-free survival in very high-risk AML and MDS patients with manageable safety.
Enhanced Progression-Free Survival with Ibrutinib Plus Rituximab in CXCR4-Mutated Waldenström Macroglobulinemia: Insights from a Pooled Analysis
A pooled analysis of prospective studies shows ibrutinib plus rituximab improves progression-free survival in Waldenström macroglobulinemia patients with CXCR4 mutations compared to ibrutinib alone, supporting routine CXCR4 testing and comb
Advancing Treatment in Relapsed/Refractory Plasma Cell Myeloma: Dual-Nanobody BCMA CAR T-Cell Therapy Shows Promising Efficacy and Safety
Nanobody-based dual-targeting BCMA CAR T-cell therapy demonstrates high response rates and manageable safety in relapsed/refractory plasma cell myeloma, including high-risk subgroups.
Maintenance Romidepsin Therapy Post-AHCT in Peripheral T-Cell Lymphoma: Feasibility and Outcomes from a Multicenter Phase 2 Study
Maintenance therapy with romidepsin following autologous hematopoietic stem-cell transplantation (AHCT) in peripheral T-cell lymphoma (PTCL) demonstrated feasibility and an estimated 2-year progression-free survival (PFS) of 62%, though the
PET-Guided BrECADD Therapy: A Breakthrough for Older Patients with Advanced-Stage Classic Hodgkin Lymphoma
This phase II HD21 trial cohort demonstrates that PET-guided BrECADD chemotherapy is feasible, effective, and well-tolerated in older patients with advanced-stage classic Hodgkin lymphoma, achieving high complete remission and survival rate
Ferritin-Guided Iron Supplementation in Blood Donors: Evidence Synthesis and Clinical Implications from the FORTE Trial and Related Studies
Iron supplementation guided by ferritin levels effectively mitigates iron deficiency and anaemia in regular blood donors, offering a practical alternative or adjunct to extending donation intervals.
Advancing Care in Older Adult T-Cell Leukemia/Lymphoma: Phase 2 Trial of Moga-CHOP-14 Combination Therapy
A phase 2 study demonstrated that combining mogamulizumab with CHOP chemotherapy improves progression-free survival in older patients with adult T-cell leukemia/lymphoma, highlighting a promising first-line option.
Ultrasensitive Circulating Tumor DNA as a Superior Biomarker for Remission Assessment in Large B-cell Lymphoma
Detection of circulating tumor DNA (ctDNA) provides a highly prognostic method for assessing remission in large B-cell lymphoma, outperforming conventional imaging and promising improved patient outcomes.
Oral Realgar-Indigo Naturalis Formula Matches Arsenic Trioxide Efficacy in Non-High-Risk Acute Promyelocytic Leukemia: Insights from a Multicenter Randomized Trial
A pivotal multicenter randomized trial demonstrates that oral Realgar-Indigo naturalis formula (RIF) combined with ATRA is non-inferior to arsenic trioxide (ATO) plus ATRA, providing a simplified consolidation regimen for non-high-risk APL
Sustained Remission in Acute Promyelocytic Leukemia with ATO-ATRA and Gemtuzumab Ozogamicin: Long-Term Phase 2 Outcomes
A phase 2 study shows that combining all-trans retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin yields a 94% cure rate in acute promyelocytic leukemia with favorable safety over five years.
APOLLO Trial Highlights Superior Efficacy of Arsenic Trioxide Plus ATRA in High-Risk Acute Promyelocytic Leukemia
The phase III APOLLO trial demonstrates that arsenic trioxide combined with all-trans retinoic acid (ATRA) plus low-dose idarubicin improves event-free survival and reduces relapse rates compared to standard ATRA plus anthracycline chemothe
Reversing PD-1 Resistance in Advanced Melanoma: Insights from the SPOTLIGHT-203 Phase II Trial of BO-112 Plus Pembrolizumab
The SPOTLIGHT-203 Phase II trial demonstrates that intratumoral BO-112 combined with pembrolizumab shows promise by achieving a 25% ORR in anti-PD-1-resistant advanced melanoma with manageable safety, offering a potential new therapeutic av
Browse by specialty
Open language-specific specialty feeds and department pages.